German Reimbursement Assessment Process Fells Third Rx Victim
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly/Boehringer's Trajenta will not be marketed in Germany, as companies feel it will not meet the criteria set by authorities to get the reimbursement level it deserves.
You may also be interested in...
Germany’s IQWiG Downs Two Drugs In One Day
IQWiG turned down both GSK/Valeant’s Trobalt and Novartis’ Rasilamlo for lack of evidence of added benefit, after manufacturers’ choice of comparator deviated from those selected by the G-BA.
Germany’s Added Benefit System May Gain Credibility As It Lauds Zytiga And Cans Trajenta
Decisions by Germany’s drug benefit assessor, IQWiG, to recommend novel prostate cancer treatment Zytiga and reject me-too diabetes treatment Trajenta may allay confusion over just how well the country’s new added value assessment process is working
Germany’s Added Benefit System May Gain Credibility As It Lauds Zytiga And Cans Trajenta
Decisions by Germany’s drug benefit assessor, IQWiG, to recommend novel prostate cancer treatment Zytiga and reject me-too diabetes treatment Trajenta may allay confusion over just how well the country’s new added value assessment process is working